Roberto Gradnik

Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France.

EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA.

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.

European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium.

Zambon SpA is engaged in manufacturing pharmaceutical products. It offers anauran, anaurette, asacol, codex, fluimucil, and giason. The company is headquartered in Bresso, Italy.

Merck Serono SAS manufactures, develops, and sells pharmaceutical drugs and products. It offers medicines for diseases such as cancer, multiple sclerosis, infertility, endocrine, cardio-metabolic disorders, and psoriasis. The company was founded in 1955 and is headquartered in Lyon, France.

Stallergènes Belgium NV manufactures pharmaceutical products used for the treatment of allergies. It produces desensitization products and treatment for allergies. The firm has offices in Belgium, Czech Republic, Germany, Spain, France, Italy, the Netherlands, Austria, Poland, Portugal, and Slovenia. The company was founded in 1962 and is headquartered in Waterloo, Belgium.

IXALTIS SAS develops therapeutics to treat genitourinary tract disorders with unsatisfied medical need. The company was founded by Christian Chavy, Philippe Lluel, Roberto Gradnik, Stefano Palea, Pascal Rischmann, and Xavier Gamé in 2012 and is headquartered in Archamps, France.